https://www.selleckchem.com/pr....oducts/Verteporfin(V
751 (95%CI, 0.697-0.806) to 0.791 (95%CI, 0.737-0.845), p=0.010. Net reclassification improvement and integrated discrimination improvement were 0.648 (95%CI, 0.421-0.885, p0.001) and 0.046 (95%CI, 0.025-0.068, p0.001), respectively. A ceramide-based CERT-HBP was established to evaluate risk of MACE in hypertensive patients at high cardiovascular risk. This may improve identification of high-risk patients requiring increased attention and aggressive therapy. A ceramide-based CERT-HBP was established to evaluate ris
Like
Comment
Share
